CEO Adam Grossman received total compensation of approximately $10.2 million in 2025, consisting of a $925,000 base salary, a $1.16 million performance-based cash bonus (125% of target, tied to measurable goals including revenue, manufacturing yield, regulatory milestones, and pipeline progress), and roughly $8.1 million in equity awards (split equally between stock options and restricted stock units vesting over four years). The pay mix is heavily variable and performance-linked, well exceeding the 50-60% variable pay threshold required by policy. The company achieved record revenue of $510 million (up 20%), strong operating results, and ADMA's 3-year stock return of +229.7% vastly outperforms both the peer group median (+24.7%) and the XBI — SPDR S&P Biotech ETF (+67.6%), demonstrating that above-benchmark incentive pay is clearly justified by shareholder outcomes. The company has a compliant Dodd-Frank clawback policy in place, and prior-year say-on-pay support was a strong 88.9%, reflecting broad shareholder endorsement of the compensation structure.

KPMG LLP was only engaged in late 2024, so its tenure is approximately one year — far below the 25-year threshold that would raise independence concerns. Non-audit fees of $305,485 represent about 17% of audit fees of $1,775,600, well below the 50% threshold that would raise independence concerns. KPMG is a Big 4 firm appropriate for a company of ADMA's $2.5 billion market cap, and no material financial restatements attributable to audit failure were identified.